Document is current

Article History

Received: 11 December 2023

Revised: 17 May 2024

Accepted: 28 May 2024

First Online: 6 June 2024

Competing interests

: All authors have no conflicts of interest to declare concerning this study. They also declare any potential competing interests that have arisen in the last 3 years. Dr. Kishi has received speaker’s honoraria from Eisai, Janssen, Meiji, Otsuka, Sumitomo, Takeda, Mitsubishi-Tanabe, Kyowa, Yoshitomi, and Viatris and research grants from Eisai, JSPS KAKENHI (19K08082 and 23K06998), Japan Agency for Medical Research and Development (JP22dk0307107, JP22wm0525024, JP23dk0307122, and 24dk0307129), and the Japanese Ministry of Health, Labor and Welfare (21GC1018). Dr. Ikuta has nothing to disclose. Dr. Sakuma has received speaker’s honoraria from daiichisankyo, Eisai, Janssen, Kyowa, Meiji, Otsuka, Sumitomo, and Takeda and has received a Fujita Health University School of Medicine Research Grant for Early-Career Scientists, Grant-in-Aid for Young Scientists (B)(19K17099), Grant-in-Aid for Scientific Research (C)(23K06998), and Japan Agency for Medical Research and Development (JP22dk0307107 and JP23dk0307122). Dr. Hatano received the speaker’s honoraria from Meiji and Sumitomo, and has received Grant-in-Aid for Early-Career Scientists (23K14827). Dr. Matsuda has received the speaker’s honoraria from Janssen, Lundbeck, Sumitomo, Otsuka, Takeda, Teijin, and Viatris, and a research grant from the Japan Agency for Medical Research and Development (24dk0307126). Mr. Wilkening was supported by the Göttingen Promotionskolleg für Medizinstudierende, funded by the Jacob-Henle-Programm/Else-Kröner-Fresenius-Stiftung. Dr. Goya-Maldonado declares no conflict of interest. His work was supported by the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF: 01 ZX 1507, “PreNeSt - e:Med”). Dr. Tik has nothing to disclose. Dr. Williams is a named inventor on Stanford-owned intellectual property relating to accelerated TMS pulse pattern sequences and neuroimaging-based TMS targeting; he has served on scientific advisory boards for Otsuka, NeuraWell, Nooma, and Halo Neuroscience; and he has equity/stock options in Magnus Medical, NeuraWell, and Nooma. Dr. Kito received speaker honoraria from Inter Reha, Lundbeck, Sumitomo, Otsuka, Takeda, Teijin, and Viatris, consultant fees from Teijin, and research grants from Teijin. Dr. Iwata has received speaker’s honoraria from Eisai, Janssen, Meiji, Otsuka, Sumitomo, Takeda, Mitsubishi-Tanabe, and Viatris and research grants from Daiichi Sankyo, Eisai, Meiji, Otsuka, Sumitomo, Takeda, Tanabe-Mitsubishi, Grant-in-Aid for Scientific Research (B)(22H03003), and Japan Agency for Medical Research and Development (JP22wm0425008).